

# INHIBITOR NIJMEGEN BETHESDA ASSAYS

## FVIII INHIBITOR NIJMEGEN BETHESDA CONTROLS

INHIBITOR CONTROLS

Nijmegen Bethesda Controls



### Factor VIII Inhibitor Plasma Weak Control



#### Associated products

CRYOcheck™ Factor VIII Inhibitor Kit  
Factor IX Inhibitor Plasma Negative Control  
Factor IX Inhibitor Plasma Weak Control  
Factor VIII Inhibitor Plasma  
Factor VIII Inhibitor Plasma HCV neg  
Factor VIII Inhibitor Plasma Negative Control

#### Informations

Treatment for hemophilia A consists of injecting the missing factor VIII I.V. to prevent or stop bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.

The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control. The activity of the inhibitor is measured by the Bethesda assays or modified Nijmegen Bethesda and is expressed in BU. 1BU neutralizes 50% of the activity of FVIII for hemophilia A.

Reference	Presentation	Format
6-1800-05	Vial	25 x 0.5 mL

**Factor VIII deficient plasma without Factor VIII inhibitor.**  
**This plasma can be used for the control of the determination of Factor VIII (FVIII) inhibitor according to the Bethesda assays or modified Nijmegen Bethesda assays.**

Factor VIII Inhibitor Plasma Weak Control is made from a pool of Factor VIII deficient (<1%) human plasma.  
It contains a specific natural inhibitor directed against the activity of Factor VIII (FVIII).

#### Components

- 25 cryotubes x 0.5 mL of frozen plasma

#### Characteristics

Control titrated to the cut-off value according to HAS recommendations.

- The stability of the product is 7 days at -20 °C
- Bethesda Unit title depending on lots and tests (close to 1.5 Bethesda Unit)

